<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685750</url>
  </required_header>
  <id_info>
    <org_study_id>109752</org_study_id>
    <nct_id>NCT00685750</nct_id>
  </id_info>
  <brief_title>Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma</brief_title>
  <official_title>Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study intends to analyze the expression of specific sets of markers in tumor samples and
      in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma.
      The data obtained in this study will be used to guide future development of immunotherapies
      for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of
      markers potentially predictive of clinical response to specific anticancer therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol posting has been updated due to a protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number of
    completed subjects for 1 year and no more ongoing study subjects
  </why_stopped>
  <start_date type="Actual">April 28, 2008</start_date>
  <completion_date type="Actual">December 17, 2013</completion_date>
  <primary_completion_date type="Actual">December 17, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Expression of Tumor Antigens</measure>
    <time_frame>Before and after administration of standard of care treatment course, up to 3 months</time_frame>
    <description>The outcome presents the number of participants with expression of MAGE-A3 and NY-ESO-1 tumor antigens, after administration of standard of care treatment course compared to before administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With a Pre-identified Gene Signature (GS) to the recMAGE-A3 Cancer Immunotherapeutic</measure>
    <time_frame>Before and after administration of standard of care treatment course, up to 3 months</time_frame>
    <description>The outcome presents the number of participants with a pre-identified gene signature (GS) to the recMAGE-A3 cancer immunotherapeutic from before and after standard cancer treatment, for comparison.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Serum Proteome</measure>
    <time_frame>After administration of standard of care treatment course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Relevant Markers of the Pre-identified Gene-expression Signature as Measured by Immunohistochemical Methods and by Quantitative PCR.</measure>
    <time_frame>After administration of standard of care treatment course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of NSCLC Patients With Gene-expression Signature and Tumor Antigens in Distinct Concomitant Tumor Lesions Obtained at the Same Time From the Same Patient.</measure>
    <time_frame>After administration of standard of care treatment course</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Responding to Treatment, by Best Clinical Response Type</measure>
    <time_frame>At 6 months after the initiation of the ipilimumab therapy</time_frame>
    <description>This outcome was assessed for metastatic melanoma patients treated with ipilimumab, in order to explore the predictive value to clinical activity of pre-identified immune-related gene-expression signature, by evaluating the patient's best clinical response to this treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Lung Cancer, Non-Small Cell</condition>
  <arm_group>
    <arm_group_label>ME1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving local imiquimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-small cell lung cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ME6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cutaneous metastatic melanoma receiving ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of tumor and blood samples</intervention_name>
    <description>Samples will be collected before and after standard treatment</description>
    <arm_group_label>ME1</arm_group_label>
    <arm_group_label>ME2</arm_group_label>
    <arm_group_label>ME3</arm_group_label>
    <arm_group_label>ME4</arm_group_label>
    <arm_group_label>ME5</arm_group_label>
    <arm_group_label>ME6</arm_group_label>
    <arm_group_label>NSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (male or female) is at least 18 years of age.

          -  The investigator believes that the patient can and will comply with the requirements
             of the protocol.

          -  The patient has given his/her written informed consent to take part in the study.

          -  The investigator believes that it will be possible to obtain a tumor tissue sample of
             at least 3 mm3 before treatment and all required tumor tissues several weeks after the
             initiation of the treatment.

          -  The patient has cancer in one of the following histological types, fulfilling all of
             the characteristics listed for the respective cancer type:

        Cutaneous Melanoma, unresectable stage III or stage IV • The patient has histologically
        documented unresectable stage III or stage IV metastatic cutaneous melanoma.

        AND

        • The patient is a candidate for one of the following treatments:

          -  First-line chemotherapy with DTIC or TMZ as monotherapy [group ME1],

          -  First-line chemotherapy with an agent other than DTIC/TMZ as monotherapy or a
             combination (that may, but need not, include DTIC, TMZ, IL-2 or IFNγ) [group ME2],

          -  Second- or higherline chemotherapy with any agent or combination of agents (that may,
             but need not, include DTIC, TMZ, IL-2 or IFNγ ; i.e., systemic chemotherapy after
             isolated limb perfusion should be considered as second-line) [group ME3],

          -  Palliative irradiation of skin lesion(s)/region, irrespective of what line of
             treatment is planned [group ME4],

          -  Topical palliative treatment by imiquimod of skin lesion(s), irrespective of what line
             of treatment is planned [group ME5].

          -  First or higher line treatment with ipilimumab [group ME6].

        NSCLC, any stage if the patient is eligible for neo-adjuvant chemotherapy with subsequent
        resection • The patient has NSCLC at any stage (as defined by the International Staging
        System) if the patient is eligible for neo-adjuvant chemotherapy with subsequent resection.

        AND

        • The patient is a candidate for chemo(radio)-therapy induction doublet neoadjuvant
        chemotherapy with platinum plus a second chemotherapy drug.

        [Note: Induction radiotherapy is permitted.]

        The recruitment of patients to the NSCLC group has been ended prematurely.

        Exclusion Criteria:

          -  The patient has any family history of congenital or hereditary immunodeficiency.

          -  The patient has in the two weeks before baseline received any of the following:

          -  Chemotherapeutic agents,

          -  Immune-modulating agents such as (but not confined to) IFN-α, IL-2, BCG and
             anti-cancer therapeutic vaccines,

          -  Immunosuppressive agents such as corticosteroids [except for prednisone, or
             equivalent, &lt;0.5 mg/kg/day (absolute maximum 40 mg/day, maximum duration of treatment
             three weeks), and inhaled and topical steroids, which are allowed].

          -  The patient is currently receiving an anti cancer treatment in another clinical trial.
             However, if the patient has finished the drug administration phase of that trial and
             has entered the follow-up phase, this patient can be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostercappeln</city>
        <state>Niedersachsen</state>
        <zip>49179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hemer</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>September 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2019</results_first_posted>
  <last_update_submitted>March 22, 2019</last_update_submitted>
  <last_update_submitted_qc>March 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumor antigen</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melanoma 1 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of dacarbazine or temozolomide as first line treatment</description>
        </group>
        <group group_id="P2">
          <title>Melanoma 2 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of first line treatment other than dacarbazine or temozolomide only</description>
        </group>
        <group group_id="P3">
          <title>Melanoma 3 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of any second-or higherline chemotherapy treatment</description>
        </group>
        <group group_id="P4">
          <title>Melanoma 4 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local irradiation of cutaneous/subcutaneous tumor lesions</description>
        </group>
        <group group_id="P5">
          <title>Melanoma 5 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local imiquimod</description>
        </group>
        <group group_id="P6">
          <title>Melanoma 6 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of ipilimumab</description>
        </group>
        <group group_id="P7">
          <title>Non-Small Cell Group</title>
          <description>Non-small cell lung cancer patients nothing other than any standard of care treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Tumor sampling failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient didn't receive the treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melanoma 1 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of dacarbazine or temozolomide as first line treatment</description>
        </group>
        <group group_id="B2">
          <title>Melanoma 2 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of first line treatment other than dacarbazine or temozolomide only</description>
        </group>
        <group group_id="B3">
          <title>Melanoma 3 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of any second-or higherline chemotherapy treatment</description>
        </group>
        <group group_id="B4">
          <title>Melanoma 4 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local irradiation of cutaneous/subcutaneous tumor lesions</description>
        </group>
        <group group_id="B5">
          <title>Melanoma 5 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local imiquimod</description>
        </group>
        <group group_id="B6">
          <title>Melanoma 6 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of ipilimumab</description>
        </group>
        <group group_id="B7">
          <title>Non-Small Cell Group</title>
          <description>Non-small cell lung cancer patients nothing other than any standard of care treatment.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="20"/>
                    <count group_id="B7" value="10"/>
                    <count group_id="B8" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="12.1"/>
                    <measurement group_id="B2" value="50.7" spread="12.5"/>
                    <measurement group_id="B3" value="64.5" spread="11.5"/>
                    <measurement group_id="B4" value="77.0" spread="5.7"/>
                    <measurement group_id="B5" value="65.5" spread="13.5"/>
                    <measurement group_id="B6" value="61.8" spread="16.7"/>
                    <measurement group_id="B7" value="59.5" spread="9.7"/>
                    <measurement group_id="B8" value="63.8" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="2"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="20"/>
                    <count group_id="B7" value="10"/>
                    <count group_id="B8" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Expression of Tumor Antigens</title>
        <description>The outcome presents the number of participants with expression of MAGE-A3 and NY-ESO-1 tumor antigens, after administration of standard of care treatment course compared to before administration</description>
        <time_frame>Before and after administration of standard of care treatment course, up to 3 months</time_frame>
        <population>The analysis was performed on the Total Treated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma 1 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of dacarbazine or temozolomide as first line treatment</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 2 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of first line treatment other than dacarbazine or temozolomide only</description>
          </group>
          <group group_id="O3">
            <title>Melanoma 3 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of any second-or higherline chemotherapy treatment</description>
          </group>
          <group group_id="O4">
            <title>Melanoma 4 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local irradiation of cutaneous/subcutaneous tumor lesions</description>
          </group>
          <group group_id="O5">
            <title>Melanoma 5 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local imiquimod</description>
          </group>
          <group group_id="O6">
            <title>Melanoma 6 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of ipilimumab</description>
          </group>
          <group group_id="O7">
            <title>Non-Small Cell Group</title>
            <description>Non-small cell lung cancer patients nothing other than any standard of care treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Expression of Tumor Antigens</title>
          <description>The outcome presents the number of participants with expression of MAGE-A3 and NY-ESO-1 tumor antigens, after administration of standard of care treatment course compared to before administration</description>
          <population>The analysis was performed on the Total Treated cohort.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAGE-A3</title>
              <category_list>
                <category>
                  <title>Remained Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Remained negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not tested</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invalid testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NY-ESO-01</title>
              <category_list>
                <category>
                  <title>Remained Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Remained negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Not tested</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Invalid testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="NA">NY-ESO-01 gene signature was not assessed in this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Pre-identified Gene Signature (GS) to the recMAGE-A3 Cancer Immunotherapeutic</title>
        <description>The outcome presents the number of participants with a pre-identified gene signature (GS) to the recMAGE-A3 cancer immunotherapeutic from before and after standard cancer treatment, for comparison.</description>
        <time_frame>Before and after administration of standard of care treatment course, up to 3 months</time_frame>
        <population>The analysis was performed on the Total Treated cohort. Data was not collected for the subjects in Non-Small Cell Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma 1 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of dacarbazine or temozolomide as first line treatment</description>
          </group>
          <group group_id="O2">
            <title>Melanoma 2 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of first line treatment other than dacarbazine or temozolomide only</description>
          </group>
          <group group_id="O3">
            <title>Melanoma 3 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of any second-or higherline chemotherapy treatment</description>
          </group>
          <group group_id="O4">
            <title>Melanoma 4 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local irradiation of cutaneous/subcutaneous tumor lesions</description>
          </group>
          <group group_id="O5">
            <title>Melanoma 5 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local imiquimod</description>
          </group>
          <group group_id="O6">
            <title>Melanoma 6 Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of ipilimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Pre-identified Gene Signature (GS) to the recMAGE-A3 Cancer Immunotherapeutic</title>
          <description>The outcome presents the number of participants with a pre-identified gene signature (GS) to the recMAGE-A3 cancer immunotherapeutic from before and after standard cancer treatment, for comparison.</description>
          <population>The analysis was performed on the Total Treated cohort. Data was not collected for the subjects in Non-Small Cell Group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Remained positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Remained Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Turned Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not tested</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invalid testing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Serum Proteome</title>
        <time_frame>After administration of standard of care treatment course</time_frame>
        <population>Proteome analysis on serum samples was not performed, because they, as a consequence of the early study termination, would not have added any scientific value and would not have benefited any individual patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Group</title>
          </group>
        </group_list>
        <measure>
          <title>The Serum Proteome</title>
          <population>Proteome analysis on serum samples was not performed, because they, as a consequence of the early study termination, would not have added any scientific value and would not have benefited any individual patient.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation of Relevant Markers of the Pre-identified Gene-expression Signature as Measured by Immunohistochemical Methods and by Quantitative PCR.</title>
        <time_frame>After administration of standard of care treatment course</time_frame>
        <population>The testing was not be performed, because, as a consequence of the early study termination, no scientific value would have been brought and no patient would have benefited from it.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Group</title>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Relevant Markers of the Pre-identified Gene-expression Signature as Measured by Immunohistochemical Methods and by Quantitative PCR.</title>
          <population>The testing was not be performed, because, as a consequence of the early study termination, no scientific value would have been brought and no patient would have benefited from it.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of NSCLC Patients With Gene-expression Signature and Tumor Antigens in Distinct Concomitant Tumor Lesions Obtained at the Same Time From the Same Patient.</title>
        <time_frame>After administration of standard of care treatment course</time_frame>
        <population>The testing was not be performed, because, as a consequence of the early study termination, no scientific value would have been brought and no patient would have benefited from it.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Group</title>
          </group>
        </group_list>
        <measure>
          <title>Number of NSCLC Patients With Gene-expression Signature and Tumor Antigens in Distinct Concomitant Tumor Lesions Obtained at the Same Time From the Same Patient.</title>
          <population>The testing was not be performed, because, as a consequence of the early study termination, no scientific value would have been brought and no patient would have benefited from it.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Responding to Treatment, by Best Clinical Response Type</title>
        <description>This outcome was assessed for metastatic melanoma patients treated with ipilimumab, in order to explore the predictive value to clinical activity of pre-identified immune-related gene-expression signature, by evaluating the patient's best clinical response to this treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
        <time_frame>At 6 months after the initiation of the ipilimumab therapy</time_frame>
        <population>The analysis was performed on all the 25 subjects in the ME6 group that were tested for GS expression at Visit 1.</population>
        <group_list>
          <group group_id="O1">
            <title>GS-positive Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving ipilimumab and who tested positive for Gene Signature expression at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>GS-negative Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving ipilimumab and who tested negative for Gene Signature expression at Visit 1.</description>
          </group>
          <group group_id="O3">
            <title>GS-invalid Group</title>
            <description>Patients with cutaneous metastatic melanoma receiving ipilimumab and who had invalid tests for Gene Signature expression at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Responding to Treatment, by Best Clinical Response Type</title>
          <description>This outcome was assessed for metastatic melanoma patients treated with ipilimumab, in order to explore the predictive value to clinical activity of pre-identified immune-related gene-expression signature, by evaluating the patient's best clinical response to this treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.</description>
          <population>The analysis was performed on all the 25 subjects in the ME6 group that were tested for GS expression at Visit 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No products under investigation were used in this study. As a result, there was no collection of adverse events during this study. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Melanoma 1 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of dacarbazine or temozolomide as first line treatment</description>
        </group>
        <group group_id="E2">
          <title>Melanoma 2 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of first line treatment other than dacarbazine or temozolomide only</description>
        </group>
        <group group_id="E3">
          <title>Melanoma 3 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of any second-or higherline chemotherapy treatment</description>
        </group>
        <group group_id="E4">
          <title>Melanoma 4 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local irradiation of cutaneous/subcutaneous tumor lesions</description>
        </group>
        <group group_id="E5">
          <title>Melanoma 5 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of local imiquimod</description>
        </group>
        <group group_id="E6">
          <title>Melanoma 6 Group</title>
          <description>Patients with cutaneous metastatic melanoma receiving nothing other than standard of care treatment consisting of ipilimumab</description>
        </group>
        <group group_id="E7">
          <title>Non-Small Cell Group</title>
          <description>Non-small cell lung cancer patients nothing other than any standard of care treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely and, as a consequence, all the study objectives were not fully assessed as specified in the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

